transparency statementtechnologiesoverviewformulation technologiesdevice technologiesoverviewdpipmdismart nebuliser delivery systemsinhalation technology favorite development capabilitiesportfoliooverviewpipeline assetsinhaled other marketed and licenced productsinjectable topical marketed and licenced productsoralovervieworal drug delivery capabilitiesoral drug delivery technologiesoral drug delivery productsinvestorsoverviewlatest newsregulatory newsoverviewskyepharma rnspresentations and webcastsfinancial reportsfinancial calendaranalyst coverageshare price summaryshare price chartshare dealinggovernancewarning to shareholdersinvestor contactsannual general meetinghistorical share offeringsvectura group plc recommended all share merger with skyepharma plclatest newsoverviewemail alertscareersoverviewbogus job vacancies in usacurrent opportunitiesstudentscontacthomecompanyleadershipcompany historyour strategyhow we operatecorporate responsibilityour approachpeoplelocal communitiesenvironmentmodern slavery transparency statementtechnologiesformulation technologiesdevice technologiesdpipmdismart nebuliser delivery systemsinhalation technology favorite development capabilitiesportfoliopipeline assetsinhaled other marketed and licenced productsinjectable topical marketed and licenced productsoraloral drug delivery capabilitiesoral drug delivery technologiesoral drug delivery productsinvestorslatest newsregulatory newsskyepharma rnspresentations and webcastsfinancial reportsfinancial calendaranalyst coverageshare price summaryshare price chartshare dealinggovernancewarning to shareholdersinvestor contactsannual general meetinghistorical share offeringsvectura group plc recommended all share merger with skyepharma plclatest newsemail alertscareersbogus job vacancies in usacurrent opportunitiesstudentscontact positively transforming the lives of airwaysdisease patients positively transforming the lives of airwaysdisease patients vectura is an industry leading inhaled airways disease focused business with proprietary formulation and devices across dpi pmdi and smart nebulisation platforms . with our extensive range of technologies capabilities and collaborations we believe we can become a leader in the development of inhalation products increasing our ability to help patients suffering from respiratory diseases worldwide . vectura group plc and skyepharma plc merger completed on 10 june 2016 vectura group plc all share merger with skyepharma plc investors date 14 10 2016 140 .10 gbp change 0.90 p share price summary at a glance inhaled product development partnered and wholly owned supported by clinical and regulatory teams quality and ip device design and development dpis pmdis and smart nebulisers making vectura the partner of choice in airways diseases with a range of dpis pmdis and smart nebuliser devices for inhaled delivery of drugs to the lungs formulation development services pharmaceutical development services fee for service activities for partners device manufacturing and commercialisation dpis pmdis and smart nebulisers underpinning our product development focus through stages of pre clinical and clinical development ensuring successful commercialisation in partner s or contract manufacturing facilities oral drug development oral drug delivery solutions and technologies capabilities include formulation scale up regulatory affairs and commercial manufacture established in 1997 with head office in chippenham wiltshire uk 7 partnered marketed inhalation products and 14 other marketed products on site product and formulation development and manufacturing capability 20 pipeline products and technologies latest news 07 sep 2016 results of the annual general meeting 07 sep 2016 agm trading update 05 sep 2016 new findings confirm ultibro breezhaler consistently more effective than seretide in reducing copd flare ups across different patient groups view more news annual report download annual report presentations and webcasts 16 november 2016 jefferies 2016 london healthcare conference london october 2016 vectura group plc corporate presentation october 2016 view full list interested to learn more contact us stay informed with our email alerts registered officevectura group plcone prospect westchippenhamwiltshire sn14 6fhunited kingdomtel 44 0 1249 667700 fax 44 0 1249 667701 registered in england number 03418970 site servicescontactsitemapaccessibilityprivacy and cookie policyterms and conditions view our latest annual report here download pdf 2016 vectura group plcwebsite by design portfolio